Platelet inhibitors are a special class of drugs because one, cilostazol is actually a PDE-3 inhibitor, but due to its indications is categorized as a platelet inhibitor together with dipyridamole. Dipyridamole is a nonspecific PDE inhibitor, leading to the inhibition of platelet aggregation. It also prevents adenosine reuptake by platelets leading to increased extracellular adenosine and increased vasodilation.
Cilostazol and Dipyridamole are both platelet inhibitors and in platelets, they increase cAMP and inhibit platelet aggregation. They are clinically used for intermittent claudication, stroke or TIA prevention (w/ aspirin), cardiac stress testing (dipyridamole only due to its vasodilatory effects) and prevention of coronary stent restenosis.
submitted by โshak360(19)
Platelet inhibitors are a special class of drugs because one, cilostazol is actually a PDE-3 inhibitor, but due to its indications is categorized as a platelet inhibitor together with dipyridamole. Dipyridamole is a nonspecific PDE inhibitor, leading to the inhibition of platelet aggregation. It also prevents adenosine reuptake by platelets leading to increased extracellular adenosine and increased vasodilation.
Cilostazol and Dipyridamole are both platelet inhibitors and in platelets, they increase cAMP and inhibit platelet aggregation. They are clinically used for intermittent claudication, stroke or TIA prevention (w/ aspirin), cardiac stress testing (dipyridamole only due to its vasodilatory effects) and prevention of coronary stent restenosis.